Comparator drug sourcing in the EU is shaped by a defined set of availability, regulatory, competitive, and logistical pressures, alongside practical strategies to reduce risk and protect trial timelines.
Syed Fazle Rob, RPh
Advertisement
Head of Global Business development, AF Pharma Distribuce léčiv s.r.o.
Articles by Syed Fazle Rob, RPh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
BostonGene Expands AI-Driven Oncology Collaborations with New AstraZeneca Deal
2
Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial
3
Securing Comparator Drugs in Competitive EU Markets: Challenges and Practical Solutions
4
ACT Brief: Rethinking Representation in Cancer Trials, Positive Phase IIb SLE Data, and a Major Obesity Drug Partnership
5